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Increased tumor dose in radiotherapy 
treatment can result in a higher dose to 
adjacent organs. For the spinal cord, a tol-
erance dose of 50 Gy is reported for clini-
cally significant radiation-induced myeli-
tis and from 60 Gy an increasing probabil-
ity of radiation-induced myelopathy [11]. 
Several prognostic factors (e.g., accelerat-
ed radiotherapy, age) have been reported 
[9, 15, 26, 34] where total dose and frac-
tion size are thought to be the most im-
portant [23].
For the cervical spinal cord, a tolerance 
dose of 69.4 Gy was estimated [33]. It is 
important to note that the reports used 
were published between 1966 and 1996 
where three-dimensional (3D) planning 
was not yet standard. It is doubtful wheth-
er these data are applicable for currently 
used modern radiotherapy techniques 
such as intensity modulated radiothera-
py (IMRT) [14, 19]. A recent review rea-
soned that it is not possible to draw firm 
conclusions as data are limited due to the 
small number of patients developing my-
elopathy [22].
Chronic progressive radiation myelop-
athy (CPRM) can be preceded by delayed 
onset of Lhermitte sign (LS; 9–15 months 
after radiotherapy treatment) [6, 10, 12, 
20, 28, 32]. LS is a transient myelopathy 
with shock-like sensations from the neck 
to the extremities, typically after flexion 
of the neck, and can be evoked by differ-
ent factors including radiotherapy [2, 21, 
27, 30].
Although radiation damage to the spi-
nal cord can result in LS and rarely in 
CPRM, not much is known about these 
phenomena. Neither the tolerance dose 
of the spinal cord nor the shape of the 
dose–volume curve is established. This 
study was performed to examine poten-
tial clinical risk factors, maximum dose, 
and dose–volume distribution of the spi-
nal cord in relation to LS and CPRM in 
patients irradiated for head and neck can-
cer at one institute.
Patients and methods
The study was approved by the local In-
stitutional Review Board of MAASTRO 
clinic according to the Dutch legislation.
Tab. 1 Scoring systems for Lhermitte sign (LS) and myelopathy





Weakness or sensory loss 
not interfering with ADL









Objective neurological findings 
at or below the level treated
Mono-, para-, or 
quadriplegia
Death directly 
related to radiation 
late effects
CMS 0 1 2 3 4 5
Upper ex-
tremity
Intact Sensory symptoms 
only
Mild motor deficit with 
some functional impair-
ment
Major functional impairment 
in at least one upper extremity 
but upper extremities useful 
for simple tasks
No movement or 
flicker of movement 





Intact Walks independently 
but not normally
Walks but needs cane or 
walker
Stands but cannot walk Slight movement but 
cannot walk or stand
Paralysis
CTCAE Common Terminology Criteria for Adverse Events version 3.0, RTOG Radiation Therapy Oncology Group, EORTC European Organization for Research and Treatment of Cancer, ADL activi-
ties of daily life, CMS Cooper Myelopathy Scale.
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Patient population and 
treatment indication
Of 489 patients treated for head and neck 
tumors between January 1997 and De-
cember 2007, 437 patients with the spinal 
cord in the radiation field were eligible. 
Postoperative radiotherapy was applied 
to 110 patients and 327 patients prima-
ry radiotherapy. Chemotherapy was giv-
en to 9.6% of patients: 6.2% as concom-
itant chemotherapy and 3.4% in a neo-
adjuvant setting as part of a trial. Palli-
ative radiotherapy treatment had 33 pa-
tients (7.6%), and patients were re-irra-
diated for relapse.
Primary radiotherapy consisted of 
treatment of the primary tumor and bi-
lateral neck regions up to 46 Gy, followed 
by a boost to the primary tumor and mac-
roscopic nodes up to 68–70 Gy twice dai-
ly for 11 fractions (1.8 Gy per fraction with 
an interval > 6 h, overall treatment time 
38 days). Postoperative radiation dos-
es ranged from 46–70 Gy depending on 
the estimated risk of recurrence [24]. For 
palliation, locoregional radiotherapy with 
30–39 Gy in fractions of 3 Gy was applied 
(37.5–48.8 Gy equivalent dose for frac-
tions of 2 Gy (EQD2), linear quadratic 
with α/β = 2 Gy).
Radiotherapy treatment planning
All patients had an individual mask in the 
treatment position. Radiotherapy was ap-
plied in several phases where the spinal 
cord was shielded from radiation in the 
second phase after 46 Gy. After introduc-
tion of CT-based planning in 1996, “poor 
man’s” IMRT based on compensators was 
developed. Modern IMRT started in 2006. 
Since 2005, in vivo dosimetry is routine-
ly performed for all curative treatments. 
Accordingly, over time different parame-
ters for spinal cord contouring have been 
used: (1) simulation with the spinal cord 
area (SCA) defined as the anatomical ar-
ea between the osseous borders of verte-
brae and the anterior part of the processes 
spinosus, (2) CT-based contouring of the 
spinal cord (SC), (3) spinal cord in com-
bination with a spinal cord planning or-
gan at risk volume with a margin of 3 mm 
(SCP3), and (4) a margin of 5 mm (SCP5) 
for IMRT.









Median (range) 56 (17–126) 26 (1–126) 0.001
Age (years) Median (range) 52 (44–64) 61 (35–91) 0.001
Gender Male 12 311 n.s.
Female 5 109




Other (oral/nasal cavity, hypophar-
ynx)
1 90




Yes 0 47 n.s.
No 17 373








Half beam with direct junction 0 19 n.s.
IMRT 1 39
Other non-IMRT techniques 16 362
Neoadjuvant 
chemotherapy




Yes 1 26 n.s.
No 16 394
Fraction size ≤ 2 Gy 17 389 n.s.
> 2 Gy 0 31
Accelerated ra-
diotherapya




≤ 55 Gy 0 27 n.s.
> 55– < 68 Gy 0 34
≥ 68 Gy 17 359
LS Lhermitte sign, Max maximum, PRV planning organ volume at risk, SCA spinal cord area, SC spinal cord, SCP3, SCP5 Spi-
nal cord-PRV (3 or 5 mm margin), RT radiotherapy, AP anterior–posterior, OTT overall treatment time, n.s. not significant, n.a. 
not availableaAccelerated radiotherapy: 68 Gy, two times daily for 11 fractions (in 2 Gy fractions, OTT 38 days).




volume ≥ 45 Gy
(median, SD; range)a
SCP3:



























p value 0.042 0.024 0.012 0.018
Σ 8.2 (0–43.1) 0.8 (0–33) 0.2 (0–28.5) 0.05 (0–23.0)
LS Lhermitte sign, SCA spinal cord area, SC spinal cord, SD standard deviation; for IMRT: SCP3 spinal cord-PRV (3 mm margin)
aMedian values, standard deviation and range for the spinal cord volumes are noted in cm3.
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Planning was performed according to 
ICRU 62 [18]. Earlier the dose–volume 
histogram (DVH) calculation did not 
take into account the additional electron 
boost. The DVH was coarsely adjusted 
to correct the maximum spinal cord dose 
for the boost dose. If the distance between 
the spinal cord and the edge of the radia-
tion field was more than 7 mm, the DVH 
was not adjusted, because the dose con-
tribution to the spinal cord was thought 
to be negligible. Different scaling factors 
of DVHs were corrected by visual estima-
tion when the DVH curve asymptotically 
approached the dose axis.
Follow-up
Follow-up consisted of regular visits to the 
head and neck oncology department dur-
ing 5 years after curative radiotherapy with 
the medical history taken and physical ex-
amination done. Imaging, pathology, and 
referral to a neurologist were performed 
if indicated. After primary radiotherapy, 
a PET-CT scan (since 2003) was obtained 
3 months after treatment. Toxicity was as-
sessed by the CTCAE v3.0 score for myeli-
tis, the RTOG/EORTC score for late mor-
bidity to the spinal cord [7, 8, 35], and the 
Cooper Myelopathy Scale (. Tab. 1).
Statistical analysis
All analyses were performed with SPSS 
15.0. Due to the small number of events, 
only descriptive and univariate analyses 
were possible. The largely unequal sam-
ple size between comparison groups and 
the non-normal distribution of the da-
ta warranted that differences in continu-
ous independent factors were tested with 
the Mann–Whitney U test. Differenc-
es in frequency distributions of nominal 
or ordinal factors were tested with the χ2 
test. Follow-up time was calculated from 
the day after ending of radiotherapy until 
death or last follow-up. Patients who had 
a relapse and were retreated with RT were 
not censored for LS or myelopathy. All pa-
tients (437) were included for the analysis 
of clinical data. Dose–volume data were 
available for 387 patients (88.6%). Clinical 
data and DVH data per contouring group 
(SCA, SC, and SCP3 or SCP5) were ana-
lyzed as risk factors for myelopathy.
Results
The median follow-up was 27 months 
(range 1–126 months). For patient and 
treatment characteristics see . Tab. 2. 
No chronic myelopathy (CPRM) was 
observed with a median dose of 50 Gy 
(max. spinal dose 21.8–69 Gy) to the spi-
nal cord.
Lhermitte sign: onset 
time and duration
LS occurred in 17 of the 437 patients 
(3.9%; RTOG/EORTC: 14 grade 1 and 3 
grade 2; CTCAE scores: 16 grade 1 and 
1 grade 2). The median maximum dose to 
the spinal cord was 48.7 Gy (range 38.2–
58.6 Gy). The risk to develop LS was 2.5%, 
Abstract · Zusammenfassung




Background and purpose. The goal of this 
work was to examine toxicity and risk factors 
after irradiation of the cervical spinal cord.
Patients and methods. A total of 437 pa-
tients irradiated for a laryngeal and oropha-
ryngeal carcinoma were eligible (median fol-
low-up 27 months). Spinal cord contouring 
was defined differently over time as anatom-
ically defined spinal cord area (SCA) and the 
spinal cord on CT (SC) with a margin of 3 or 
5 mm (SCP3/SCP5).
Results. None developed chronic progres-
sive radiation myelopathy (CPRM) (maximum 
spinal dose 21.8–69 Gy); 3.9% (17/437) de-
veloped a Lhermitte sign (LS) with a median 
duration of 6 months (range 1–30 months) 
and was reversible in all patients. Risk factors 
for developing LS were younger age (52 vs. 
61 years, p < 0.001), accelerated RT (12/17 pa-
tients, p < 0.005), and dose–volume relation-
ships for SCA with ≥ 45 Gy of 14.15 cm3 and 
7.9 cm3 for patients with and without LS, re-
spectively.
Conclusion. LS is more frequently observed 
in younger patients and in patients treated 
with accelerated radiotherapy. A dose–vol-
ume relationship was seen for V45 in the case 
of SCA. For higher doses, no clear dose–vol-
ume relationships were observed.
Keywords
Spinal cord tolerance · Lhermitte sign ·  
Chronic progressive radiation myelopathy · 
Radiotherapy · Head and neck cancer
Lhermitte-Zeichen und Myelopathie nach Bestrahlung des  
zervikalen Rückenmarks bei Strahlentherapie von Kopf-Hals- 
Tumoren
Zusammenfassung
Hintergrund und Ziel. Untersuchung von 
Toxizität und Risikofaktoren nach Bestrah-
lung des zervikalen Rückenmarks.
Patienten und Methoden. Daten von 
437 Patienten mit einem Larynx- oder Oro-
pharynxkarzinom wurden untersucht (me-
diane Nachbeobachtungszeit 27 Monate). 
Die Rückenmarkkonturierung veränderte 
sich im Laufe der Zeit: zuerst anatomisch de-
finiert (SCA), später CT-basiert (SC) mit einem 
Sicherheitssaum von 3 oder 5 mm (SCP3/
SCP5).
Ergebnisse. Es wurde keine progressive ra-
diogene Myelopathie (CPRM) beobach-
tet (max. Myelondosis 21,8–69,0 Gy); 3,9% 
(17/437 Patienten) entwickelten ein Lher-
mitte-Zeichen (LS) mit einer medianen Dau-
er von 6 Monaten (1–30 Monaten), das bei al-
len Patienten reversibel war. Risikofaktoren 
für die Entwicklung des LS waren jüngeres 
Alter (52 vs. 61 Jahre, p < 0,001), akzelerier-
te RT (12/17 Patienten; p < 0,005) (. Tab. 2) 
und Dosis-Volumen-Beziehungen für SCA 
von  ≥ 45 Gy für  > 14,15 cm3 versus 7,9 cm3 
(. Tab. 3, . Fig. 1).
Schlussfolgerungen. LS wird häufiger bei 
jüngeren Patienten und nach akzelerierter 
Strahlentherapie gesehen. Eine Dosis-Volu-
men-Beziehung wurde bei der SCA für das 
V45 dokumentiert. Fϋr höhere Bestrahlungs-
dosen wurden keine Dosis-Volumen-Bezie-
hungen dokumentiert.
Schlüsselwörter
Rückenmarktoleranz · Lhermitte-Zeichen · 
Chronische progressive radiogene  
Myelopathie · Strahlentherapie ·  
Kopf- und Halstumoren
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3.7%, and 3.9% at 3, 6, and 12 months, re-
spectively. The median onset time for LS 
in the entire group was 3 months (range 
1–10 months). The median duration of 
LS was 6 months (range 1–30 months). 
There was no significant difference for 
onset time and duration between grades 1 
and 2. None of 7 patients re-irradiated for 
relapse with the spinal cord in the radio-
therapy treatment field with a prescribed 
mean dose of 52.7 Gy developed LS.
Imaging and treatment
In 3 of 17 patients with LS (17.6%), imag-
ing was obtained at the time of LS symp-
toms. A MRI scan showed no changes of 
demyelinization in 2 patients. A PET-CT 
scan in the third patient showed no ab-
normalities with regard to the spinal cord. 
Three patients were referred to a neurol-
ogist. One of these patients was treated 
with corticosteroids, but treatment was 
stopped due to side effects.
Risk factors
Age was a significant prognostic fac-
tor. Patients developing LS were young-
er (median 52 years; . Tab. 2). Twelve 
out of 17 had accelerated radiotherapy. 
Occurrence of LS was evenly distributed 
over time (1997: 1; 1998: 2; 2000 and 2001: 
1; 2002 and 2003: 3; 2005: 4; 2006: 2 pa-
tients). The median maximum dose and 
the maximum dose to the spinal cord were 
higher for the non-LS group, but not sig-
nificantly different. None of the patients 
in the SCP5 and SC group developed LS.
Dose–volume relationship LS
A significant difference in irradiated vol-
umes at specific dose levels was found in 
3 out of 4 spinal cord contouring groups: 
LS was seen for larger volumes at lower 
dose (≥ 45 Gy) and small volumes with 
doses of ≥ 50 Gy (. Tab. 3, . Fig. 1). For 
all patients independent of the contouring 
group, the median volume receiving doses 
of ≥ 45 Gy and ≥ 50 Gy were 11 cm3 (LS pa-
tients 16.6 cm3, non-LS 10.8 cm3, not sig-
nificant) and 0.3 cm3 (LS 0.04 cm3, non-
LS 0.3 cm3, not significant), respectively. 
For the SCA group, spinal cord volumes 
irradiated to a dose ≥ 50 Gy were medi-
an 0 cm3 for both LS and non-LS patients, 
and 0.06 and 0.90 cm3, respectively, for LS 
and non-LS patients of the SCP3 group.
Discussion
The occurrence rate of LS due to irradia-
tion of cervical spinal cord is reported as 
3.6% [15] which we could confirm with 
our results of 3.9%. The median time un-
til occurrence is 3 months with a median 
duration of 6 months (longest duration 
> 1 year). Similar time frames have been 
reported with onset 1–6 months after ra-
diotherapy and spontaneous regression 
after 2–9 months [6, 10, 20, 21, 26]. The 
median follow-up time for patients with a 
LS was significantly shorter due to the fact 
that patients were included until the study 
cut-off date. This is, however, acceptable, 
because the onset of LS was observed as 
early as 1 month.
The lowest spinal cord dose related to LS 
was described at dose levels of 29 Gy and 
36.52 Gy, which is comparable to 38.2 Gy 
in our study [20]. We found a slightly lower 
dose of 48.7 Gy compared to a reported dose 
of ≥ 50 Gy to the cervical cord described as 
being significant for developing LS [15]. Sig-
nificantly more LS were reported if daily 
fractions were ≥ 2 Gy [15] which we cannot 
confirm as all patients with LS were irradi-
ated with a fraction size ≤ 2 Gy. However, for 
patients irradiated with accelerated radio-
therapy twice daily during the last week, a 
significant correlation was seen. LS was ob-
served in 12/17 patients treated by accelerat-
ed RT two times daily 1.8 Gy with an interval 
of > 6 h during the last week. These findings 
are supported in the literature where a LS in-
cidence of 3.9% was reported for accelerated 
schedules using fraction sizes of 1.2 Gy [15].
The incidence of LS was equally dis-
tributed over the years of our observa-
tion period from 1997–2007, parallel to 
the stepwise introduction of modern ra-
diotherapy techniques and the use of on-
line dosimetry. Radiation techniques do 
not seem to have influenced the number 
of events.
Another potential risk factor investi-
gated was dose–volume relation. Signifi-
cant dose–volume relationships with larg-
er volumes of 14.15 cm3 and a dose ≥ 45 Gy 
were observed when anatomically defined 
contouring of the spinal cord was used. If 
CT-based contouring with or without a 
margin of 3 mm is used, very small vol-
umes of 0–0.06 cm3 containing high-
er dose areas of ≥ 50 Gy constitute a risk. 
This seems logical, because non-CT based 
definition of the spinal cord results auto-
matically in larger irradiated volumes of 
the spinal cord. However, CT-based con-
touring with an added margin of 5 mm 
has not yet resulted in LS due to the small 
patient numbers (n = 3), like in the recent 
literature [16]. It is remarkable that the dif-
ference between LS and no LS is not ob-
served in the high dose areas: non-LS pa-
tients had received higher maximum dos-
es (not significant) and V50–54 at larger 
median volumes (significant) than LS pa-















40 45 50 55 60 65
Dose (Gy)
At 45 Gy p =.042
LS
No LS
Fig. 1 9 Dose–volume 
relationship for ana-
tomically defined spi-
nal cord area (SCA) 
and Lhermitte sign 
(LS). The vertical line 
represents significant 
difference in irradiat-
ed volumes and dose. 
Error bars show 95% 




group were all < 1 cm3 and, therefore, 
probably too small to be consistently treat-
ed: due to the mobility of the spinal cord 
despite mask mobilization. The maximum 
spinal cord dose in a very small volume is, 
thus, likely to be blurred. Inoue et al. [17] 
report on 1 patient with D0.5cm3 of 127 Gy 
(BED2) to the cervical spine with a tran-
sient myelitis, however, after re-irradiation 
[17]. To our knowledge, no dose–volume 
response data of the spinal cord with re-
gard to LS are known in the literature.
Patients developing LS were signifi-
cantly younger (52 versus 61 years) which 
is in concordance with the study of Leung 
et al. [26] who reported a lower incidence 
of LS (2.8%) in patients with an age of 
60 years or older.
On MRI and PET imaging, no chang-
es potentially corresponding with LS were 
observed in our patients imaged. Esik et 
al. [13] reported 2 patients with chronic 
LS after radiotherapy where the MRI did 
not reveal any pathological signs of demy-
elination. A FDG-PET scan showed an in-
creased FDG uptake in the irradiated spi-
nal cord. Lengyel et al. [25] presented a 
patient with a partially recovering radia-
tion myelopathy: repeated PET scans re-
vealed increased FDG and O15butanol up-
take with no C11methionine accumulation 
in the irradiated spinal cord. At autopsy 
axonal and neuronal loss with little vas-
cular changes, inflammation, or prolifer-
ation was seen.
The occurrence rate of CPRM due to ir-
radiation of the cervical spinal cord with 
46.6–60 Gy is reported to range from 0.18–
1.9% [29, 31]. Determining factors for my-
elopathy reported were the integral irradi-
ated spinal cord volume, the dose distri-
bution in the spinal cord, and influence of 
bath dose highest for a 2 mm field and ab-
sent for 8 mm fields [3, 4, 5]. Recovery of 
CPRM is estimated as being 61% [1]. A re-
cent review estimated the risk of myelopa-
thy at total doses of 50 Gy, 60 Gy, and ca. 
69 Gy as 0.2%, 6%, and 50% using fractions 
of 1.8–2 Gy [22]. We observed no CPRM 
despite irradiation of the spinal cord to 
high doses of 69 and 60 Gy with a medi-
an follow-up of 27 months and 15 months, 
respectively. The median dose to the spi-
nal cord was about 50 Gy which is often re-
ported in the literature as a cut-off point 
for an acceptable dose to the spinal cord. 
Patients with a spinal cord dose of at least 
50 Gy had a significantly shorter follow-up, 
but both groups had an equal percentage 
of follow-up of ≥ 10 months which is about 
the latest onset time for LS in our group 
and, thus, too short to observe CPRM. The 
reason for this is most presumably the fact 
that patients with a higher dose to the spi-
nal cord often had larger tumors and it was 
deemed acceptable to irradiate the spinal 
cord to a higher dose than 50 Gy in order 
to ensure good tumor coverage.
LS due to radiotherapy treatment 
seems to be a different biological entity 
than CPRM. First, LS is usually revers-
ible. Only late onset LS may develop in-
to CPRM [6, 10, 12, 20, 28, 32]. Second, 
LS developed at maximum doses as low 
as 38.2 Gy. Third, demyelination of axo-
ns by radiotherapy leads to reduced speed 
of action potentials. This can be resolved 
by a higher sodium channel density, but 
this causes increased glucose metabolism 
and, therefore, greater tissue perfusion. 
Increased FDG and O15butanol uptake as 
well autopsy findings with lack of struc-
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